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RESEARCH PAPER
Pasteurized Akkermansia muciniphila increases whole-body energy expenditure
and fecal energy excretion in diet-induced obese mice
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and Patrice D. Cani a
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ABSTRACT
Accumulating evidence points to Akkermansia muciniphila as a novel candidate to prevent or treat
obesity-relatedmetabolic disorders. We recently observed, in mice and in humans, that pasteurization
of A. muciniphila increases its beneficial effects onmetabolism. However, it is currently unknown if the
observed beneficial effects on body weight and fat mass gain are due to specific changes in energy
expenditure. Therefore, we investigated the effects of pasteurized A. muciniphila on whole-body
energy metabolism during high-fat diet feeding by using metabolic chambers. We confirmed that
daily oral administration of pasteurized A. muciniphila alleviated diet-induced obesity and decreased
food energy efficiency. We found that this effect was associated with an increase in energy expendi-
ture and spontaneous physical activity. Strikingly, we discovered that energy expenditure was
enhanced independently from changes in markers of thermogenesis or beiging of the white adipose
tissue. However, we found in brown and white adipose tissues that perilipin2, a factor associated with
lipid droplet and known to be altered in obesity, was decreased in expression by pasteurized
A. muciniphila. Finally, we observed that treatment with pasteurized A. muciniphila increased energy
excretion in the feces. Interestingly, we demonstrated that this effect was not due to the modulation
of intestinal lipid absorption or chylomicron synthesis but likely involved a reduction of carbohydrates
absorption and enhanced intestinal epithelial turnover.
In conclusion, this study further dissects the mechanisms by which pasteurized A. muciniphila
reduces body weight and fat mass gain. These data also further support the impact of targeting
the gut microbiota by using specific bacteria to control whole-body energy metabolism.
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Introduction
Obesity and its ensuingmetabolic disorders, including
insulin resistance and cardiometabolic complications,
represent a growing epidemic and economic burdens
for public health authorities.1,2 Moreover, it is cur-
rently largely accepted that the gut microbiota can
influence whole-body metabolism by affecting energy
balance.3 The recognition that the gut microbiota is
a key factor involved in the development of obesity-
related disorders raises the prospect to study single
intestinal microorganisms and combinations thereof
with potential benefit for health.4-6 In this context,
several studies have highlighted the multiple health-
promoting effects of Akkermansia muciniphila, an
intestinal mucin-degrading symbiont that is consid-
ered currently as a next-generation beneficial
microbe.7 A. muciniphila belongs to the phylum
Verrucomicrobia, is a Gram-negative bacteria, and
represents 1-5% of the total human microbiome in
healthy conditions.8 The abundance ofA. muciniphila
is severely reduced in several pathological conditions
(i.e., obesity, type 2 diabetes, inflammatory bowel
diseases, and appendicitis).9-15 We demonstrated
that oral administration ofA. muciniphila counteracts
diet-induced obesity (DIO) in mice.16 Importantly,
the beneficial effects of the bacteria on cardiometa-
bolic features were thereafter supported by others
using various pathological murine models.17-22
Recently, we discovered that pasteurization of the
bacteria (i.e., treatment for 30 min at 70°C) made it
more effective than the live bacteria in preventing
DIO in mice.23 This finding was recently confirmed
CONTACT Patrice D. Cani Patrice.cani@uclouvain.be UCLouvain, Université Catholique De Louvain, LDRI, Metabolism and Nutrition Research Group,
Av. E. Mounier, 73 Box B1.73.11, B-1200 Brussels, Belgium
Supplemental data for this article can be accessed on the publisher’s website
GUT MICROBES
2020, VOL. 11, NO. 5, 1231–1245
https://doi.org/10.1080/19490976.2020.1737307
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
in a first proof-of-concept pilot human intervention.24
In addition to the major observation that treatment
was well tolerated and declared safe in individuals
suffering from metabolic syndrome, we reported
that pasteurizedA.muciniphila significantly alleviated
the worsening of the disease observed in the placebo
condition.24
Several studies have reported positive correlations
between the abundance of A. muciniphila and energy
expenditure or thermogenesis.25-27 However, none of
these studies investigated its impact on whole-body
energy metabolism by using indirect calorimetry, and
the effect of pasteurized A. muciniphila on whole-
body energy features remains unknown. Therefore,
we first aimed to confirm the protective effect of
pasteurized A. muciniphila in a DIO model. Second,
we aimed to determine whether this protective effect
was mediated through the modulation of energy
expenditure and physical activity by using the gold
standard method (i.e., indirect calorimetry). Mice
were housed in metabolic chambers during the last
seven days of a 5-week experiment consisting of daily
oral gavage of pasteurizedA.muciniphila concomitant
to a high-fat diet (HFD) exposure.
Results
Pasteurized A. muciniphila prevents diet-induced
obesity
Pasteurized A. muciniphila significantly reduced
HFD-induced body weight gain and fat mass gain
(Figure 1a–d), without affecting cumulative food
intake (Figure 1g). More specifically, the fat mass
gain was already significantly lower as early as
2 weeks after the beginning of the treatment with
pasteurizedA. muciniphila (Figure 1b). Consistently,
at the end of the experiment, we found that the
different adipose depots (SAT: subcutaneous; EAT:
epididymal; VAT: visceral) were significantly smaller
in the treated group, except for the brown adipose
tissue (BAT), which remained similar between the
three groups (Figure 1e). Hence, the total adiposity
index was significantly lower in the treated mice
(Figure 1f). Given that the animals were gaining
less weight without changes in the total energy
ingested, we observed a significant reduction in
energy efficiency in the treated group compared to
the HFD group (Figure 1h). Of note, the absolute
lean mass did not vary significantly between groups
over the course of the experiment (Sup Figure 1a).
However, in concordance with the evolution of the
fat mass in the different group, when expressing the
lean mass as the percentage of body weight, this
parameter significantly decreased over time in the
HFD group when compared to both control group
and treated group (Sup Figure 1b).
Pasteurized A. muciniphila enhances energy
expenditure, oxygen consumption and physical
activity in HFD mice
To further dissect themechanism explaining whymice
treatedwith pasteurizedA.muciniphila are gaining less
weight and fat mass, mice were housed individually in
metabolic chambers during the last week of experi-
ment. The results from indirect calorimetry revealed
that HFD-fed mice exhibited a reduced energy expen-
diture compared to their lean littermates (Figure 2a).
The effect of the HFDwas completely abolished by the
treatment with pasteurized A. muciniphila, since mice
were spending the same amount of energy than the
normal diet (ND)-fedmice (Figure 2a). This protection
was mirrored by a trend in increasing CO2 production
(Figure 2b) and a significant enhancement of VO2
consumption in treated mice (Figure 2c). In addition,
mice treated with pasteurized A. muciniphila exhibited
a significant increase in locomotor activity when com-
pared with control, while this parameter was not
altered by the exposition to HFD (Figure 2d). As
expected, the respiratory exchange ratio (RER) was
significantly lower in HFD-fed groups (Figure 2e).
This outcome was in agreement with a preference for
lipid utilization inHFD-fed groups and glucose utiliza-
tion in ND-fed mice.
Pasteurized A. muciniphila does not modulate
SAT beiging or BAT function
To determine the contribution of thermogenesis in
increased energy expenditure upon pasteurized
A. muciniphila supplementation, we quantified the
mRNA expression of several markers related to
BAT function. As depicted in Figure 3a, an HFD
induced a strong and significant downregulation of
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Elovl6, Elovl3 and, Cidea, while UCP-1 expression
was enhanced and Dio2 expression was unchanged.
We did not find a marked treatment effect on any of
those markers. Histological analysis of BAT further
validated those data; we noticed an enhanced
whitening process upon HFD, as defined by devel-
opment of enlarged lipid droplets. Pasteurized
A. muciniphila treatment decreases the whitening
and the lipid droplet size of the BAT by approxi-
mately 30–40% but this effect did not reach signifi-
cance (P = .11 versus ND) (Figure 3b). To further
extend our initial hypothesis, we investigated mar-
kers of beiging program and lipolysis in the SAT.
We observed an important downregulation of the
expression of UCP-1, Elovl3, and Cidea upon an
HFD, while TBX1 and PGC1α expression levels
Figure 1. Pasteurized A. muciniphila modulates body composition and reduces energy efficiency in HFD-fed mice.
(a, b) Body weight evolution (g) (a) and fat mass evolution (g) (b) over a 5-week period. Mean ± s.e.m, *p < .05, **p < .01,
***p < .001 compared to ND, #p < .05, ##p < .01, ###p < .001 compared to HFD (n = 7). (c, d) Body weight gain (g) (c) and fat mass
gain (g) (d) after a 5-week period (n = 7). (e) Weight of different white adipose tissue depots and BAT (mg) (n = 7). (f) Adiposity
index corresponding to the sum of the subcutaneous, visceral, and epididymal adipose depot weights in mg divided by a factor of
1000 (n = 7); (g, h) Cumulative food intake (g) and energy efficiency corresponding to the ratio between body weight gain and
energy intake (Kcal/g) (h) calculated on the basis of the first 4 weeks of treatment. Data are presented as the mean ± s.e.m, *p < .05,
**p < .01, ***p < .001 (n = 7). Blue: ND mice, pink: HFD mice, and orange: HFD mice supplemented with pasteurized A. muciniphila.
Data were analyzed using two-way ANOVA followed by Tukey’s post hoc test for a and b and according to one-way ANOVA followed
by Tukey’s post hoc test for c–h.
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were unaffected either by the HFD or treatment.
The expression of CD137 was somewhat higher in
the HFD-fed groups, but this did not reach statis-
tical significance (P = .2 versus ND). Treatment
with pasteurized A. muciniphila did not signifi-
cantly modulate those alterations. Finally, both
markers of lipolysis (HSL and ATGL) were statisti-
cally unaffected either by diet or treatment
(Figure 3c).
Pasteurized A. muciniphila influences expression
of lipid-droplet regulator associated proteins
Lipid droplet surfaces are decorated by the presence
of specific proteins that play important roles in the
regulation of adipocyte metabolism, notably with
regards to caloric input, storage, morphologic fea-
tures, and energy demands.28 Consistent with this
notion, we investigated whether pasteurized
A. muciniphilamight influence those lipid metabo-
lism regulators in SAT and BAT. Perilipin1 expres-
sion was found to be similar between groups in both
tissues. Since phosphorylation is known to be
a strong inducer of perilipin1 cellular action, we
also quantified phosphorylated-perilipin1 protein
levels in SAT and found no major diet or treatment
effect (Figure 4a,b). Whereas perilipin1 was found
to be unaffected, a significant downregulation of
perilipin2 was observed upon treatment in both
tissues when compared to control (Figure 4a). As
perilipin2 is ubiquitous, we also quantified its
expression in muscles, as well as markers of oxida-
tive metabolism. By using RT-qPCR, it was shown
that perilipin2 expression was not altered either in
the gastrocnemius or in the soleus. Moreover, mar-
kers of fatty acid oxidation were similar between
groups (Sup Figure 2a–h). Finally, we noticed
a diet-related downregulation of Cidec mRNA
expression in BAT, which was partially counter-
acted by the treatment. Interestingly, this effect
was not observed in the SAT (Figure 4a).
Pasteurized A. muciniphila increases fecal energy
content and reduces expression of carbohydrates
transporters
To further explore other physiologic pathways by
which energy could have been spent in the treated
mice, we measured fecal energy content by calori-
metric bomb. We found that pasteurized
A. muciniphila significantly increased fecal caloric
content when compared to both untreated groups
(Figure 5a). To decipher the mechanism under-
lying this effect, markers related to lipid, peptides
and carbohydrates absorption were assessed in the
jejunum. The results from qPCR analysis demon-
strated a significant overexpression of CD36 and
FABP1 under HFD conditions. Additionally, while
MTTP mRNA expression was not affected by any
condition, ApoB mRNA expression was decreased
with an HFD (Figure 5b). Interestingly, pasteur-
ized A. muciniphila was not able to restore any of
those markers to a level comparable to the ND
group. Despite alterations in lipid absorption, the
treatment successfully blunted HFD-induced
hypercholesterolemia. By contrast, plasma trigly-
cerides and nonesterified fatty acids (NEFAs) were
unchanged in all groups (Figure 5c). Finally, the
transcript levels of the main glucose transporters
GLUT2 and SGLT1 mRNA were significantly
decreased in the group supplemented with pas-
teurized A. muciniphila when compared to the
ND group (Figure 5e). A similar decrease was
measured for the fructose transporter GLUT5
Figure 2. Pasteurized A. muciniphila increases energy expenditure and physical activity in HFD-fed mice.
(a) Light, dark, and total cycle energy expenditure (Kcal h−1 kg body weight−1) measured in metabolic chambers during indirect
calorimetry studies (n = 6–7). (b) Light, dark, and total CO2 production (ml h
−1 kg body weight−1) (n = 7). (c) Light, dark, and total O2
consumption (ml h−1 kg body weight−1) (n = 7). (d) Light, dark, and, total XY locomotor activity (Beam Breaks h−1). (e) Respiratory
exchange ratio (VCO2/VO2) (n = 7). Blue: ND mice, pink: HFD mice, and orange: HFD mice supplemented with pasteurized
A. muciniphila. Data are presented as the mean ± s.e.m, *p < .05 compared to ND, #p < .05 compared to HFD for every hour
24 h graphs. Data are presented as the mean ± s.e.m, *p < .05, **p < .01, ***p < .001 for the column graphs. Data were analyzed by
ANCOVA adjusted for lean mass (column graphs) or repeated measures two-way ANOVA followed by Tukey’s post hoc test (24 h
graphs).
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Figure 3. Pasteurized A. muciniphila does not modulate markers of beiging in the SAT and metabolism of BAT in HFD-fed mice.
(a) mRNA expression of UCP-1, Elovl6, Elovl3, Cidea, Dio2 in the BAT (n = 6–7). (b) Representative histology of paraformaldehyde-
fixed brown adipocyte, after hematoxylin & eosin staining, shown at 20x magnification, scale bar = 100 µm (n = 7) and histological
score of lipid droplets. (c) mRNA expression of UCP-1, PGC1a, Elovl3, Cidea, TBX1, CD137, HSL, ATGL in SAT (n = 6–7). Blue: ND mice,
pink: HFD mice, and orange: HFD mice supplemented with pasteurized A. muciniphila. Data are presented as the mean ± s.e.m,
*p < .05, **p < .01, ***p < .001. Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test.
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mRNA, whereas the expression of PEPT1 mRNA
remained unchanged (Figure 5e).
Pasteurized A. muciniphila modulates markers of
intestinal epithelial cell turnover
We next tested if part of the excreted energy could
come from enhanced epithelial cell turnover. For this
purpose, we quantified the expression of intectin and
cyclin D1 (CCDN1), two markers of intestinal cell
turn over. Our data showed that intectin expression
was significantly reduced by an HFD in jejunum
(Figure 5d). Interestingly, this downregulation was
partially corrected upon treatment with the pasteur-
ized A. muciniphila cells to levels statistically similar
to NDmice (Figure 5d). In line with this, pasteurized
A. muciniphila significantly increased the transcript
level of cyclin D1 in the group supplemented with
when compared to the HFD-fed group, but this
effect was restricted to the jejunum (Figure 5d).
Discussion
In this study, we confirmed our original finding
that pasteurized A. muciniphila treatment attenu-
ates DIO in terms of body weight gain and body
Figure 4. Mice treated with pasteurized A. muciniphila are characterized by a specific reduced expression of perilipin2 in adipose
tissue.
(a) mRNA expression of Cidec, Perilipin1 (Plin1) and Perilipin2 (Plin2) in subcutaneous adipose tissue and brown adipose tissue
(n = 6–7). (b) Western blot analysis of SAT protein extracts, expression of Plin1 and its phosphorylated form (pPlin1). Ratio
quantification was measured by densitometry (n = 6). Blue: ND mice, pink: HFD mice, and orange: HFD mice supplemented with
pasteurized A. muciniphila. Data are presented as the mean ± s.e.m, *p < .05, **p < .01, ***p < .001. Data were analyzed by one-way
ANOVA followed by Tukey’s post hoc test.
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Figure 5. Pasteurized A. muciniphila increased fecal energy content without affecting markers of lipid absorption and chylomicron
synthesis in the jejunum but modulated carbohydrate absorption and intestinal epithelial cell turnover.
(a) Fecal energy content (kcal g feces−1) (n = 7). (b) mRNA expression of FATP4, CD36, FABP1, MTTP and ApoB in jejunum (n = 7). (c)
Plasma non-esterified fatty acid, triglyceride and total cholesterol (n = 7). (d) mRNA expression of Intectin in jejunum, and CCND1 in
jejunum and colon (n = 7). (e) mRNA expression of GLUT2, SGLT1, GLUT5 and PEPT1 in jejunum (n = 6–7). Blue: ND mice, pink: HFD
mice, and orange: HFD mice supplemented with pasteurized A. muciniphila. Data are presented as the mean ± s.e.m, *p < .05,
**p < .01, ***p < .001. Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test.
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composition.23,24 By using metabolic chambers
and indirect calorimetry, we found that the phe-
notype could be explained by several mechanisms
including an enhanced energy expenditure and
physical activity and an increased fecal energy
excretion in the pasteurized A. muciniphila treated
mice. Of note, the drop in RER observed with an
HFD, which is highlighting an increased oxidation
of fat, was not affected by the treatment. However,
the observed increase in CO2 production and O2
consumption clearly corroborates an overall
increase in oxidation of fat compared to the HFD
groups. When compared to the ND group, loco-
motor activity was also increased by pasteurized
A. muciniphila. However, the fact that decreased
energy expenditure was observed with an HFD,
despite a similar locomotor activity, further sup-
ports that divergence in body weight gain could
not be entirely attributable to disparities in physi-
cal activity. Moreover, we may not rule out that
the observed changes in physical activity may sim-
ply be secondary to the lower body weight gain
observed in pasteurized A. muciniphila treated
mice.
Accordingly, we next examined markers of two
well-known energy producing processes, known to
be associated with protection against obesity-related
metabolic diseases, called thermogenesis and
beiging.29-31 We noticed that restoration of the
impaired BAT whitening and activity were not the
major mechanisms for the energy expenditure-
enhancing action of pasteurized A. muciniphila.
Moreover, the hypothesis of stimulated beiging was
excluded, since the defective SAT activity with an
HFD was not restored by the treatment. Taken
together, these results suggest that the beneficial effect
on energy expenditure induced by the pasteurized
A. muciniphila is independent from BAT and white
adipose tissue (WAT) activities. Conversely, recent
studies provide strong evidence of positive correla-
tions between the increased abundance of
A. muciniphila following a bile diversion procedure
or supplementation with tea or coffee extract and
browning processes.26,27 A recent study using a five
times higher dose of live A. muciniphila than the one
used in our study, observed a slight upregulation of
UCP-1.25 The confrontation of this recent literature
with our data acknowledges the previous formulated
hypothesis that the live and the pasteurized bacterium
might act beneficially but through different metabolic
pathways.24 Among the various regulators of adipo-
cyte metabolism, lipid droplet-associated proteins
have recently appeared to interfere with energy expen-
diture and obesity-related parameters.32-34 Mice over-
expressing perilipin1 are obese-resistant and share
attractive similarities with our model, notably in
terms of enhanced energy expenditure and oxygen
consumption.35,36 Moreover, obesity is characterized
by a reduced expression of perilipin1 in WAT.37-39
Importantly, perilipin1 phosphorylation results in
increased access of lipase to lipid droplets and stimu-
lated lipolysis.28,40Here, in addition to the lack ofHFD
effect on its expression, we found that the treatment
did not modulate perilipin1, either in terms of mRNA
expression or phosphorylated protein. The unaffected
HSL and ATGL expression in SAT corroborates these
findings. Nevertheless, we noticed a differential effect
of the treatment on the perilipins. While perilipin1
was unaffected by any condition, we observed an
adipose-specific perilipin2 downregulation, in parallel
with the restoration of Cidec expression in BAT upon
pasteurizedA. muciniphila treatment. Although those
datawarrants further confirmation at the protein level,
it is worth noting that perilipin2 is usually found
upregulated in obesity.41,42 More strikingly, multiple
studies demonstrated that perilipin2 knockout mice
developed a highly reproducible obesity-resistant
phenotype43-47 associated with modulation of the gut
microbiota composition.48 Finally, Cidec expression
was reduced in obese individuals and upregulated
following bariatric surgery-induced weight loss.49,50
In line with our previous work, we demonstrated
that administration of pasteurized A. muciniphila
cells increased fecal energy content, along with
reduced plasma total cholesterol.23 To determine
the possible mechanism for the current observation,
we next examined markers of nutrient absorption.
We found that markers of lipid absorption were not
affected by the treatment. Along with these findings,
we further speculated that lipid utilization and oxi-
dation might be enhanced in peripheral tissues (i.e.,
muscles). This assumption was excluded, since we
did not find any significant differences for genes
related to fatty acid oxidation in muscles between
the groups. However, we cannot draw definitive
conclusions regarding the nonbeneficial effect of
the bacterium on fatty acid oxidation or lipolysis,
since our model was not characterized by major
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alterations in these markers. This outcome may be
due to the relatively short-term exposure to an HFD
(i.e., 5 weeks versus 8–16 weeks).
Importantly, we discovered that pasteurized
A. muciniphila significantly altered the expression
of several major intestinal carbohydrate transporters.
Indeed, we found that GLUT2, GLUT5 and SGLT1
mRNA were significantly decreased, thereby sug-
gesting that pasteurized A. muciniphila decreases
glucose and fructose absorption in the jejunum.
Altogether, those results strongly suggest that the
increased energy loss observed in the feces might
be associated with a reduced absorption of carbohy-
drates. We can further speculate that those mechan-
isms might partially account for the improved
glucose tolerance observed in previous study upon
supplementation of pasteurized A. muciniphila.23
We have previously shown that an HFD or
a western diet reduces the expression of intectin,51-53
a marker of intestinal epithelial cell renewal.54 In the
present study, we found that the increased energy
excretion was accompanied by the restoration of the
expression of intectin in the jejunum and increased
transcript level of CyclinD1, anothermarker of intest-
inal epithelial turnover. Interestingly, we previously
discovered that the expression of intectin was
enhanced following supplementation with
oligofructose,51,53 a prebiotic known to increase the
abundance of A. muciniphila in rodents.51,55 Of note,
expression of CyclinD1, among others, is known to be
decreased in absence of gutmicrobiota, supporting the
notion that the gut microbiota is able to affect intest-
inal cell renewal.56,57 Although further research is
needed, this interesting finding might suggest that
pasteurized A. muciniphila promotes the turnover of
intestinal mucosa throughout the intestinal tract,
thereby not only contributing to the maintenance of
the gut barrier but also contributing to higher energy
loss in the feces via the shedding of intestinal epithelial
cells.
In conclusion, by using gold-standard and state-of
-the-art methods, we discovered that pasteurized
A. muciniphila administration reduced body-weight
and fat mass gain through several complementary
mechanisms such as an increased whole-body
energy expenditure, as well as an increased excretion
of energy in the feces which can be potentially
explained by a higher intestinal epithelial cell turn-
over as well as a reduction of the absorption of
different carbohydrates. Altogether, our data high-
light that the protective effect of pasteurized
A. muciniphila on HFD-induced obesity implies
enhanced energy expenditure and physical activity.
Moreover, by studying the potential pathways
explaining the leakage of energy, we bring to light
an interesting effect of the bacteria on carbohydrates
absorption, intestinal turnover and possibly on an
increased fecal energy content in the treated mice.
Materials and methods
Mice and experimental design
C57BL/6J 8-week old male mice (n = 7 per group)
were purchased from Janvier (France) and were
housed in a specific and opportunistic pathogen
free (SOPF) animal facility with a controlled tem-
perature-humidity and 12 h light-dark cycle. Mice
had free access to water and food. Upon delivery,
mice underwent an acclimatization period of one
week during which they were fed with a normal
diet (ND) (AIN96Mi, Research diet, New
Brunswick, NJ, USA). Mice were matched accord-
ing to fat mass and body weight and divided into
three groups. During the following 5 weeks, mice
were fed a ND or an HFD (60% fat and 20%
carbohydrates (kcal per 100 g), D12492i,
Research diet New Brunswick, NJ, USA) and
were treated daily with an oral gavage of either
2 × 108 CFU/180 µl of pasteurized A. muciniphila
(ATTC BAA-835) in sterile PBS containing 2.5%
glycerol or 180 µl of vehicle solution (PBS contain-
ing 2.5% glycerol). Pasteurization consisted of heat
treatment at 70°C for 30 min of fresh
A. muciniphila produced, as previously
described.23 Body weight and body composition
were measured once a week using 7.5 mHz TD-
NMR (LF50 minispec, Bruker). Food intake was
assessed weekly. Cumulative food intake and
energy efficiency were calculated based on the 4
first weeks. Mice were separated one week before
indirect calorimetry measurement for acclimation.
In the final week of the experiment, fecal samples
were harvested after a 48 h period and fecal energy
content was measured using a bomb calorimeter
(Staufen, Germany). All data shown are compiled
from two independent experiment (n = 3–4 for
each set of experiment, leading to n = 7/group in
total).
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All mouse experiments were approved by and per-
formed in accordance with the guideline of the local
ethics committee (Ethics Committee of the Université
Catholique de Louvain for Animal Experiments spe-
cifically approved this study that received the agree-
ment number 2017/UCL/MD/005). Housing
conditions were specified by the Belgian Law of
29 May 2013, regarding the protection of laboratory
animals (agreement number LA1230314).
Indirect calorimetry study
At 4 weeks of treatment, the mice were placed indivi-
dually in metabolic chambers (Labmaster, TSE sys-
tems GmbH, Bad Homburg, Germany) for seven
days. Mice were housed with free access to food and
water (ND or HFD) and were acclimated to the
chambers for 24 h before experimental measure-
ments. The mice were analyzed for RER (calculated
as vCO2/vO2), whole energy expenditure, oxygen
consumption, and carbon dioxide production using
indirect calorimetry (Labmaster, TSE systems
GmbH). The last three parameters were expressed as
a function of whole-body weight. Locomotor activity
was recorded using an infrared light beam-based
locomotion monitoring system (expressed as Beam
Breaks count per hour). The measurement period
accounted for six and a half days in total, starting at
6 pm the first day and finishing at 6 am the last day.
Inside the chambers, measurements were taken every
15 minutes. Values were then summed by hour. For
each mouse, a mean value was obtained for
every hour of a 24 h day cycle and was calculated
from the basis of 6 different measurements (6 days of
measurements). Accordingly, the final data represen-
tation (total, day or night) corresponds to all the
values measured and summed (light phase or dark
phase). The means (n = 7) were finally compared
between groups.
Tissue sampling
At the end of the treatment period, the animals were
anesthetized with isoflurane (Forene; Abbott). Blood
was sampled from the cava vein. After exsanguination
and tissue sampling, the mice were killed by decapita-
tion. Adipose depots (subcutaneous, epididymal,
mesenteric and brown) were precisely dissected and
weighed. The intestinal segments, muscles
(gastrocnemius and soleus) and adipose tissues were
immersed in liquid nitrogen and stored at −80°C for
further analysis. Pieces of BAT were sampled for
further histological analyses.
Histological analysis
BAT depots were fixed in 4% paraformaldehyde for
24 h at room temperature before processing for
paraffin embedding. Hematoxylin and eosin staining
was performed using standard protocols on 5-μm
tissue sections. Images were obtained using
a SCN400 slide scanner and Digital Image Hub soft-
ware (Leica Biosystems, Wetzlar, Germany) and
were captured using Leica Image Viewer Software
(National Institutes of Health, Bethesda, Maryland,
USA). A minimum of 5 high-magnification fields
were analyzed per mouse.
RNA preparation and real-time qPCR analysis
Total RNA was prepared from collected tissues by
using TriPure reagent from Roche. cDNA was pre-
pared by reverse transcription of 1 µg total RNA
using a Reverse Transcription System Kit
(Promega, Madison, Wisconsin, USA). Real-time
PCR was performed with the CFX96 Real-time
PCR system and CFX manager 3.1 software (Bio-
Rad, Hercules, California, USA) using GoTaq qPCR
Master Mix (Promega) for detection, according to
the manufacturer’s instructions. RPL19 RNA was
chosen as the housekeeping gene, and data were
analyzed according to the 2−ΔΔCT method. The
identity and purity of the amplified product were
assessed by melting curve analysis at the end of
amplification. The primer sequences for the tar-
geted mouse genes are presented in Table 1.
Western blotting
Subcutaneous adipose tissues were homogenized in
RIPA buffer (Tris HCL 25 mM, NaCl 150 mM, 1%
NP-40, 0,1% sodium dodecyl sulfate) supplemented
with a cocktail of protease inhibitors and phosphatase
inhibitors. Equal amounts of proteins were separated
by SDS–PAGE and transferred to nitrocellulosemem-
branes. Membranes were incubated 1 h at room tem-
perature with anti-phospho-perilipin1 (1:5000, Vala
Science, #4856) and overnight at 4°C with anti-
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perilipin1 (1:1000, Cell signaling #9349). Both anti-
bodies were diluted in Tris-buffered saline-Tween-20
containing 1% bovine serum albumin. The loading
control was HSP90 (1:500, sc-13119, Santa Cruz).
Signal quantification was acquired with an
Amersham Imager 600 (GEHealthcare) and analyzed
by ImageQuant TL software.
Biochemical analysis
Plasma triglycerides and plasma total cholesterol
were measured in cava blood using kits coupling
the enzymatic reaction and spectrophotometric
detection of the final product (Diasys Diagnostic
and System, Holzheim, Germany). Plasma non-
esterified fatty acid levels were assessed using
a commercially available enzymatic assay
(Randox Laboratories, Crumlin, UK).
Statistical analysis
The data are presented as the means ± s.e.m. The
statistical significance of difference was evaluated by
one-way or two-way ANOVA followed by Tukey’s
post hoc multiple comparison test. Analysis of covar-
iance (ANCOVA) with the lean mass (g) as covari-
able, was performed on data relative to energy
expenditure, VO2 and CO2 consumption divided by
body weight. For ANCOVA, assumptions of homo-
geneity of regression and independence of the covari-
ate to the treatment effects were respected. The data
with a superscript symbol (* vs ND, # vs HFD) are
significantly different (*p < .05; **p < .01; ***p < .001).
Except ANCOVA, all the analyses were performed
using GraphPad Prism version 8.00 for Windows
(GraphPad Software). ANCOVA was conducted
using SPSS v.23.0 (IBM Corporation). The presence
of outliers was assessed using the Grubbs test.
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